凱萊英(002821.SZ)擬3000萬元收購CRO公司冠勤醫藥100%股權
格隆匯9月7日丨凱萊英(002821.SZ)宣佈,公司與標的公司冠勤醫藥原股東天津盛勤醫藥科技合夥企業(有限合夥)、樑青簽署《股權轉讓協議》,公司以自有資金合計3000萬元人民幣收購冠勤醫藥原股東持有的100%股權。交易完成後,公司將持有冠勤醫藥100%股權。
冠勤醫藥成立於2007年,經過十餘年的深耕細作,已成為國內領先的CRO公司之一。冠勤醫藥已建立臨牀前及臨牀兩大服務平台,業務範圍涵蓋臨牀前研究項目管理和註冊事務,臨牀研究項目管理、SMO服務、數據管理與統計、第三方稽查、藥物警戒等,通過高質量的一站化服務模式,在醫藥研發各個階段都能為客户提供最優效的解決方案。
天津盛勤醫藥科技合夥企業(有限合夥)同意對標的公司2020年度實現的淨利潤數進行承諾,標的公司在業績承諾期內經審計確認的淨利潤應不低於人民幣400萬元。業績承諾期為完成交割後的2020年度剩餘期間,若該次股權轉讓於2020年9月完成交割,則2020年9-12月為業績承諾期,以此類推。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.